<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - ACCOLATE- zafirlukast tablet, film coated</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">ACCOLATE- zafirlukast tablet,
film coated<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AACCOLATE%2D%20Zafirlukast%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D5550433b%2D8c9c%2D4378%2D058f%2D6bb724c4f18c%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-03.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-03.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
src=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-03.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-04.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-04.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
src=
"image.cfm?type=img&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-04.jpg&amp;setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ZAFIRLUKAST%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=ZAFIRLUKAST"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ZAFIRLUKAST"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ZAFIRLUKAST[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ZAFIRLUKAST/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ZAFIRLUKAST/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ZAFIRLUKAST/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=ZAFIRLUKAST[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00377&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0310-0401-60, 0310-0402-60</span></li>
<li style="list-style: none"><span id="item-code-s"></span></li>
<li><span id="item-code-s"></span></li>
<li><span id="item-code-s"><strong>Packager:</strong> AstraZeneca
Pharmaceuticals LP</span></li>
</ul>
<ul class="drug-information">
<li><span id="item-code-s"><strong>Category:</strong> <span id=
"category" class="orangetext">HUMAN PRESCRIPTION DRUG
LABEL</span></span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated November 15, 2013</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;type=pdf&amp;name=5550433b-8c9c-4378-058f-6bb724c4f18c"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;type=zip&amp;name=ACCOLATE"
target="_blank">XML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li><a href="#">DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="ID_6d02df95-5076-47a0-3794-6683185f8eae" id=
"ID_6d02df95-5076-47a0-3794-6683185f8eae"></a> <a name="section-1"
id="section-1"></a>
<p class="First">Zafirlukast is a synthetic, selective peptide
leukotriene receptor antagonist (LTRA), with the chemical name
4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide.
The molecular weight of zafirlukast is 575.7 and the structural
formula is:</p>
<div class="Figure"><a name="id323" id="id323"></a> <img src=
"image.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-01.jpg"
alt="chem"></div>
<p>The empirical formula is: C<span class=
"Sub">31</span>H<span class="Sub">33</span>N<span class=
"Sub">3</span>O<span class="Sub">6</span>S</p>
<p>Zafirlukast, a fine white to pale yellow amorphous powder, is
practically insoluble in water. It is slightly soluble in methanol
and freely soluble in tetrahydrofuran, dimethylsulfoxide, and
acetone.</p>
<p>ACCOLATE is supplied as 10 and 20 mg tablets for oral
administration.</p>
<p><span class="Bold">Inactive Ingredients:</span> Film-coated
tablets containing croscarmellose sodium, lactose, magnesium
stearate, microcrystalline cellulose, povidone, hypromellose, and
titanium dioxide.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="williamsonbk1131388273647" id=
"williamsonbk1131388273647"></a> <a name="section-2" id=
"section-2"></a>
<div class="Section" data-sectioncode="43679-0"><a name=
"ID_953ebd61-356d-4ea6-a6a1-40bcc6186c36" id=
"ID_953ebd61-356d-4ea6-a6a1-40bcc6186c36"></a> <a name=
"section-2.1" id="section-2.1"></a>
<h2>Mechanism of Action:</h2>
<p class="First">Zafirlukast is a selective and competitive
receptor antagonist of leukotriene D<span class="Sub">4</span> and
E<span class="Sub">4</span> (LTD<span class="Sub">4</span> and
LTE<span class="Sub">4</span>), components of slow-reacting
substance of anaphylaxis (SRSA). Cysteinyl leukotriene production
and receptor occupation have been correlated with the
pathophysiology of asthma, including airway edema, smooth muscle
constriction, and altered cellular activity associated with the
inflammatory process, which contribute to the signs and symptoms of
asthma. Patients with asthma were found in one study to be 25-100
times more sensitive to the bronchoconstricting activity of inhaled
LTD<span class="Sub">4</span> than nonasthmatic subjects.</p>
<p><span class="Italics">In vitro</span> studies demonstrated that
zafirlukast antagonized the contractile activity of three
leukotrienes (LTC<span class="Sub">4</span>, LTD<span class=
"Sub">4</span> and LTE<span class="Sub">4</span>) in conducting
airway smooth muscle from laboratory animals and humans.
Zafirlukast prevented intradermal LTD<span class=
"Sub">4</span>-induced increases in cutaneous vascular permeability
and inhibited inhaled LTD<span class="Sub">4</span>-induced influx
of eosinophils into animal lungs. Inhalational challenge studies in
sensitized sheep showed that zafirlukast suppressed the airway
responses to antigen; this included both the early- and late-phase
response and the nonspecific hyperresponsiveness.</p>
<p>In humans, zafirlukast inhibited bronchoconstriction caused by
several kinds of inhalational challenges. Pretreatment with single
oral doses of zafirlukast inhibited the bronchoconstriction caused
by sulfur dioxide and cold air in patients with asthma.
Pretreatment with single doses of zafirlukast attenuated the early-
and late-phase reaction caused by inhalation of various antigens
such as grass, cat dander, ragweed, and mixed antigens in patients
with asthma. Zafirlukast also attenuated the increase in bronchial
hyperresponsiveness to inhaled histamine that followed inhaled
allergen challenge.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name=
"ID_1c98c695-e71b-4ee7-54b4-177d5e898a36" id=
"ID_1c98c695-e71b-4ee7-54b4-177d5e898a36"></a> <a name=
"section-2.2" id="section-2.2"></a>
<h2>Clinical Pharmacokinetics and Bioavailability:</h2>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_88e82327-5b20-4db6-2681-61c16a220484" id=
"ID_88e82327-5b20-4db6-2681-61c16a220484"></a> <a name=
"section-2.2.1" id="section-2.2.1"></a>
<h3><span class="Italics">Absorption</span></h3>
<p class="First">Zafirlukast is rapidly absorbed following oral
administration. Peak plasma concentrations are generally achieved 3
hours after oral administration. The absolute bioavailability of
zafirlukast is unknown. In two separate studies, one using a high
fat and the other a high protein meal, administration of
zafirlukast with food reduced the mean bioavailability by
approximately 40%.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_f27c15a3-b418-4036-d4a1-6a925537faad" id=
"ID_f27c15a3-b418-4036-d4a1-6a925537faad"></a> <a name=
"section-2.2.2" id="section-2.2.2"></a>
<h3><span class="Italics">Distribution</span></h3>
<p class="First">Zafirlukast is more than 99% bound to plasma
proteins, predominantly albumin. The degree of binding was
independent of concentration in the clinically relevant range. The
apparent steady-state volume of distribution (Vss/F) is
approximately 70 L, suggesting moderate distribution into tissues.
Studies in rats using radiolabeled zafirlukast indicate minimal
distribution across the blood-brain barrier.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_42a70b11-702b-45df-96a7-0a34cee9a9db" id=
"ID_42a70b11-702b-45df-96a7-0a34cee9a9db"></a> <a name=
"section-2.2.3" id="section-2.2.3"></a>
<h3><span class="Italics">Metabolism</span></h3>
<p class="First">Zafirlukast is extensively metabolized. The most
common metabolic products are hydroxylated metabolites which are
excreted in the feces. The metabolites of zafirlukast identified in
plasma are at least 90 times less potent as LTD<span class=
"Sub">4</span> receptor antagonists than zafirlukast in a standard
<span class="Italics">in vitro</span> test of activity.
<span class="Italics">In vitro</span> studies using human liver
microsomes showed that the hydroxylated metabolites of zafirlukast
excreted in the feces are formed through the cytochrome P450 2C9
(CYP2C9) pathway. Additional <span class="Italics">in vitro</span>
studies utilizing human liver microsomes show that zafirlukast
inhibits the cytochrome P450 CYP3A4 and CYP2C9 isoenzymes at
concentrations close to the clinically achieved total plasma
concentrations (see <a href="#williamsonbk1131387802291">Drug
Interactions</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_7282101c-2da8-44e3-878f-e1e9730b7dfb" id=
"ID_7282101c-2da8-44e3-878f-e1e9730b7dfb"></a> <a name=
"section-2.2.4" id="section-2.2.4"></a>
<h3><span class="Italics">Excretion</span></h3>
<p class="First">The apparent oral clearance (CL/f) of zafirlukast
is approximately 20 L/h. Studies in the rat and dog suggest that
biliary excretion is the primary route of excretion. Following oral
administration of radiolabeled zafirlukast to volunteers, urinary
excretion accounts for approximately 10% of the dose and the
remainder is excreted in feces. Zafirlukast is not detected in
urine.</p>
<p>In the pivotal bioequivalence study, the mean terminal half-life
of zafirlukast is approximately 10 hours in both normal adult
subjects and patients with asthma. In other studies, the mean
plasma half-life of zafirlukast ranged from approximately 8 to 16
hours in both normal subjects and patients with asthma. The
pharmacokinetics of zafirlukast are approximately linear over the
range from 5 mg to 80 mg. Steady-state plasma concentrations of
zafirlukast are proportional to the dose and predictable from
single-dose pharmacokinetic data. Accumulation of zafirlukast in
the plasma following twice-daily dosing is approximately 45%.</p>
<p>The pharmacokinetic parameters of zafirlukast 20 mg administered
as a single dose to 36 male volunteers are shown with the table
below.</p>
<a name="_RefID0EHLAC" id="_RefID0EHLAC"></a>
<div class="scrollingtable">
<table>
<caption><span>Mean (% Coefficient of Variation) pharmacokinetic
parameters of zafirlukast following single 20 mg oral dose
administration to male volunteers (n=36)</span></caption>
<colgroup>
<col width="12%">
<col width="13%">
<col width="11%">
<col width="12%">
<col width="11%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="5">
<dl class="Footnote">
<dt><a href="#footnote-reference-1" name="footnote-1" id=
"footnote-1">*</a></dt>
<dd>Median and range</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">C<span class=
"Sub">max</span></span></p>
<p><span class="Bold">ng/ml</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">t<span class=
"Sub">max</span></span><a class="Sup" href="#footnote-1" name=
"footnote-reference-1" id="footnote-reference-1">*</a></p>
<p><span class="Bold">h</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">AUC</span></p>
<p><span class="Bold">ng•h/mL</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">t<span class=
"Sub">1/2</span></span></p>
<p><span class="Bold">h</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">CL/f</span></p>
<p><span class="Bold">L/h</span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">326 (31.0)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">2 (0.5 - 5.0)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">1137 (34)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">13.3 (75.6)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">19.4 (32)</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_454265a2-a37e-4a34-bbb6-f0683b058eee" id=
"ID_454265a2-a37e-4a34-bbb6-f0683b058eee"></a> <a name=
"section-2.2.5" id="section-2.2.5"></a>
<h3><span class="Italics">Special Populations</span></h3>
<p class="First">Gender: The pharmacokinetics of zafirlukast are
similar in males and females. Weight-adjusted apparent oral
clearance does not differ due to gender.</p>
<p>Race: No differences in the pharmacokinetics of zafirlukast due
to race have been observed.</p>
<p>Elderly: The apparent oral clearance of zafirlukast decreases
with age. In patients above 65 years of age, there is an
approximately 2-3 fold greater C<span class="Sub">max</span> and
AUC compared to young adult patients.</p>
<p>Children: Following administration of a single 20 mg dose of
zafirlukast to 20 boys and girls between 7 and 11 years of age, and
in a second study, to 29 boys and girls between 5 and 6 years of
age, the following pharmacokinetic parameters were obtained:</p>
<div class="scrollingtable">
<table>
<colgroup>
<col width="17%">
<col width="33%">
<col width="33%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Parameter</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Children age 5-6 years Mean (%
Coefficient of Variation)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Children age 7-11 years
Mean</span></p>
<p><span class="Bold">(% Coefficient of Variation)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">C<span class="Sub">max</span> (ng/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">756 (39%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">601 (45%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">AUC (ng•h/mL)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">2458 (34%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">2027 (38%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">t<span class="Sub">max</span> (h)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">2.1 (61%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">2.5 (55%)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">CL/f (L/h)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">9.2 (37%)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">11.4 (42%)</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>Weight unadjusted apparent clearance was 11.4 L/h (42%) in the
7-11 year old children and 9.2 L/h (37%) in the 5-6 year old
children, which resulted in greater systemic drug exposures than
that obtained in adults for an identical dose. To maintain similar
exposure levels in children compared to adults, a dose of 10 mg
twice daily is recommended in children 5-11 years of age (see
<a href="#williamsonbk1131387848681">DOSAGE AND
ADMINISTRATION</a>).</p>
<p>Zafirlukast disposition was unchanged after multiple dosing (20
mg twice daily) in children and the degree of accumulation in
plasma was similar to that observed in adults.</p>
<p>Hepatic Insufficiency: In a study of patients with hepatic
impairment (biopsy-proven cirrhosis), there was a reduced clearance
of zafirlukast resulting in a 50-60% greater C<span class=
"Sub">max</span> and AUC compared to normal subjects.</p>
<p>Renal Insufficiency: Based on a cross-study comparison, there
are no apparent differences in the pharmacokinetics of zafirlukast
between renally-impaired patients and normal subjects.</p>
<p><span class="Bold">Drug-Drug Interactions:</span> The following
drug interaction studies have been conducted with zafirlukast (see
<a href="#williamsonbk1131387802291">PRECAUTIONS, Drug
Interactions</a>).</p>
<dl>
<dt>•</dt>
<dd>Coadministration of multiple doses of zafirlukast (160 mg/day)
to steady-state with a single 25 mg dose of warfarin (a substrate
of CYP2C9) resulted in a significant increase in the mean AUC
(+63%) and half-life (+36%) of S-warfarin. The mean prothrombin
time increased by approximately 35%. The pharmacokinetics of
zafirlukast were unaffected by coadministration with warfarin.</dd>
<dt>•</dt>
<dd>Coadministration of zafirlukast (80 mg/day) at steady-state
with a single dose of a liquid theophylline preparation (6 mg/kg)
in 13 asthmatic patients, 18 to 44 years of age, resulted in
decreased mean plasma concentrations of zafirlukast by
approximately 30%, but no effect on plasma theophylline
concentrations was observed.</dd>
<dt>•</dt>
<dd>Coadministration of zafirlukast (20 mg/day) or placebo at
steady-state with a single dose of sustained release theophylline
preparation (16 mg/kg) in 16 healthy boys and girls (6 through 11
years of age) resulted in no significant differences in the
pharmacokinetic parameters of theophylline.</dd>
<dt>•</dt>
<dd>Coadministration of zafirlukast dosed at 40 mg twice daily in a
single-blind, parallel-group, 3-week study in 39 healthy female
subjects taking oral contraceptives, resulted in no significant
effect on ethinyl estradiol plasma concentrations or contraceptive
efficacy.</dd>
<dt>•</dt>
<dd>Coadministration of zafirlukast (40 mg/day) with aspirin (650
mg four times daily) resulted in mean increased plasma
concentrations of zafirlukast by approximately 45%.</dd>
<dt>•</dt>
<dd>Coadministration of a single dose of zafirlukast (40 mg) with
erythromycin (500 mg three times daily for 5 days) to steady-state
in 11 asthmatic patients resulted in decreased mean plasma
concentrations of zafirlukast by approximately 40% due to a
decrease in zafirlukast bioavailability.</dd>
<dt>•</dt>
<dd>Coadministration of zafirlukast with fluconazole, a moderate
CYP2C9 inhibitor, resulted in increased</dd>
<dd>plasma levels of zafirlukast, by approximately 58% (90% CI:28,
95). The clinical significance of this</dd>
<dd>interaction is unknown. Zafirlukast exposure is likely to be
increased by other moderate and strong</dd>
<dd>CYP2C9 inhibitors. Coadministration of zafirlukast with
itraconazole, a strong CYP3A4 inhibitor,</dd>
<dd>caused no change in plasma levels of zafirlukast.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectioncode="34092-7"><a name=
"ID_ac6268c6-9fc8-476e-fc8a-c22753cfb723" id=
"ID_ac6268c6-9fc8-476e-fc8a-c22753cfb723"></a> <a name=
"section-2.3" id="section-2.3"></a>
<h2>Clinical Studies:</h2>
<p class="First">Three U.S. double-blind, randomized,
placebo-controlled, 13-week clinical trials in 1380 adults and
children 12 years of age and older with mild-to-moderate asthma
demonstrated that ACCOLATE improved daytime asthma symptoms,
nighttime awakenings, mornings with asthma symptoms, rescue
beta<span class="Sub">2</span>-agonist use, FEV<span class=
"Sub">1</span>, and morning peak expiratory flow rate. In these
studies, the patients had a mean baseline FEV<span class=
"Sub">1</span> of approximately 75% of predicted normal and a mean
baseline beta<span class="Sub">2</span>-agonist requirement of
approximately 4-5 puffs of albuterol per day. The results of the
largest of the trials are shown in the table below.</p>
<a name="_RefID0ECCAE" id="_RefID0ECCAE"></a>
<div class="scrollingtable">
<table>
<caption><span>Mean Change from Baseline at Study End
Point</span></caption>
<colgroup>
<col width="34%">
<col width="19%">
<col width="10%"></colgroup>
<tfoot>
<tr>
<td align="left" colspan="3">
<dl class="Footnote">
<dt><a href="#footnote-reference-2" name="footnote-2" id=
"footnote-2">*</a></dt>
<dd>p&lt;0.05, compared to placebo</dd>
</dl>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">ACCOLATE</p>
<p>20 mg twice daily</p>
<p>N=514</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"bottom">
<p class="First">Placebo</p>
<p>N=248</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Daytime Asthma symptom score</p>
<p>(0-3 scale)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-0.44<a class="Sup" href="#footnote-2" name=
"footnote-reference-2" id="footnote-reference-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-0.25</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Nightime Awakenings</p>
<p>(number per week)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-1.27<a class="Sup" href="#footnote-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-0.43</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Mornings with Asthma Symptoms</p>
<p>(days per week)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-1.32<a class="Sup" href="#footnote-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-0.75</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Rescue β<span class="Sub">2</span>-agonist use</p>
<p>(puffs per day)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-1.15<a class="Sup" href="#footnote-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">-0.24</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">FEV<span class="Sub">1</span> (L)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+0.15<a class="Sup" href="#footnote-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+0.05</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Morning PEFR (L/min)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+22.06<a class="Sup" href="#footnote-2">*</a></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+7.63</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First">Evening PEFR (L/min)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+13.12</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top">
<p class="First">+10.14</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>In a second and smaller study, the effect of ACCOLATE on most
efficacy parameters was comparable to the active control (inhaled
cromolyn sodium 1600 mcg four times per day) and superior to
placebo at end point for decreasing rescue beta<span class=
"Sub">2</span>-agonist use (figure below).</p>
<div class="Figure"><a name="id269162272" id="id269162272"></a>
<img src=
"image.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-02.jpg"
alt="Mean B2-agonist use (puffs/day)"></div>
<p>In these trials, improvement in asthma symptoms occurred within
one week of initiating treatment with ACCOLATE. The role of
ACCOLATE in the management of patients with more severe asthma,
patients receiving antiasthma therapy other than as-needed, inhaled
beta<span class="Sub">2</span>-agonists, or as an oral or inhaled
corticosteroid-sparing agent remains to be fully characterized.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="ID_d8a37c86-5d36-4837-be89-4ffb78297237" id=
"ID_d8a37c86-5d36-4837-be89-4ffb78297237"></a> <a name="section-3"
id="section-3"></a>
<p class="First">ACCOLATE is indicated for the prophylaxis and
chronic treatment of asthma in adults and children 5 years of age
and older.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="ID_d1d186b2-8025-46df-698b-4f94690e4c89" id=
"ID_d1d186b2-8025-46df-698b-4f94690e4c89"></a> <a name="section-4"
id="section-4"></a>
<p class="First">ACCOLATE is contraindicated in patients who are
hypersensitive to zafirlukast or any of its inactive
ingredients.</p>
<p>ACCOLATE is contraindicated in patients with hepatic impairment
including hepatic cirrhosis.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">WARNINGS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34071-1"><a name="ID_54d868c7-a9e6-4a6c-72b6-78e591ca2d7e" id=
"ID_54d868c7-a9e6-4a6c-72b6-78e591ca2d7e"></a> <a name="section-5"
id="section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"williamsonbk1131388093117" id="williamsonbk1131388093117"></a>
<a name="section-5.1" id="section-5.1"></a>
<h2>Hepatotoxicity:</h2>
<p class="First">Cases of life-threatening hepatic failure have
been reported in patients treated with ACCOLATE. Cases of liver
injury without other attributable cause have been reported from
post-marketing adverse event surveillance of patients who have
received the recommended dose of ACCOLATE (40 mg/day). In most, but
not all post-marketing reports, the patient’s symptoms abated and
the liver enzymes returned to normal or near normal after stopping
ACCOLATE. In rare cases, patients have either presented with
fulminant hepatitis or progressed to hepatic failure, liver
transplantation and death. In extremely rare post-marketing cases,
no clinical symptoms or signs suggestive of liver dysfunction were
reported to precede the latter observations.</p>
<p>Physicians may consider the value of liver function testing.
Periodic serum transaminase testing has not proven to prevent
serious injury but it is generally believed that early detection of
drug-induced hepatic injury along with immediate withdrawal of the
suspect drug enhances the likelihood for recovery.</p>
<p>Patients should be advised to be alert for signs and symptoms of
liver dysfunction (eg, right upper quadrant abdominal pain, nausea,
fatigue, lethargy, pruritus, jaundice, flu-like symptoms, and
anorexia) and to contact their physician immediately if they occur.
Ongoing clinical assessment of patients should govern physician
interventions, including diagnostic evaluations and treatment.</p>
<p>If liver dysfunction is suspected based upon clinical signs or
symptoms (eg, right upper quadrant abdominal pain, nausea, fatigue,
lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and
enlarged liver), ACCOLATE should be discontinued.</p>
<p>Liver function tests, in particular serum ALT, should be
measured immediately and the patient managed accordingly. If liver
function tests are consistent with hepatic dysfunction, ACCOLATE
therapy should not be resumed. Patients in whom ACCOLATE was
withdrawn because of hepatic dysfunction where no other
attributable cause is identified should not be re-exposed to
ACCOLATE (see <a href="#williamsonbk1131387955212">PRECAUTIONS,
Information for Patients</a> and <a href=
"#williamsonbk1131387977133">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_2c91b81d-fdc2-4d17-1ea8-3d0389bc3f26" id=
"ID_2c91b81d-fdc2-4d17-1ea8-3d0389bc3f26"></a> <a name=
"section-5.2" id="section-5.2"></a>
<h2>Bronchospasm:</h2>
<p class="First">ACCOLATE is not indicated for use in the reversal
of bronchospasm in acute asthma attacks, including status
asthmaticus. Therapy with ACCOLATE can be continued during acute
exacerbations of asthma.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"williamsonbk1131388212897" id="williamsonbk1131388212897"></a>
<a name="section-5.3" id="section-5.3"></a>
<h2>Concomitant Warfarin Administration:</h2>
<p class="First">Coadministration of zafirlukast with warfarin
results in a clinically significant increase in prothrombin time
(PT). Patients on oral warfarin anticoagulant therapy and ACCOLATE
should have their prothrombin times monitored closely and
anticoagulant dose adjusted accordingly (see <a href=
"#williamsonbk1131387802291">PRECAUTIONS, Drug
Interactions</a>).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"42232-9"><a name="ID_de22f893-34fe-4210-3098-87c5ea971ce7" id=
"ID_de22f893-34fe-4210-3098-87c5ea971ce7"></a> <a name="section-6"
id="section-6"></a>
<div class="Section" data-sectioncode="34076-0"><a name=
"williamsonbk1131387955212" id="williamsonbk1131387955212"></a>
<a name="section-6.1" id="section-6.1"></a>
<h2>Information for Patients:</h2>
<p class="First">Patients should be told that a rare side effect of
ACCOLATE is hepatic dysfunction, and to contact their physician
immediately if they experience symptoms of hepatic dysfunction (eg.
right upper quadrant abdominal pain, nausea, fatigue, lethargy,
pruritus, jaundice, flu-like symptoms, and anorexia). Liver failure
resulting in liver transplantation and death has occurred in
patients taking zafirlukast (see <a href=
"#williamsonbk1131388093117">WARNINGS, Hepatotoxicity</a> and
<a href="#williamsonbk1131387977133">ADVERSE REACTIONS</a>).</p>
<p>ACCOLATE is indicated for the chronic treatment of asthma and
should be taken regularly as prescribed, even during symptom-free
periods. ACCOLATE is not a bronchodilator and should not be used to
treat acute episodes of asthma. Patients receiving ACCOLATE should
be instructed not to decrease the dose or stop taking any other
antiasthma medications unless instructed by a physician. Patients
should be instructed to notify their physician if neuropsychiatric
events occur while using ACCOLATE (see <a href=
"#powellk11242666522624">PRECAUTIONS, Neuropsychiatric Events</a>).
Women who are breast-feeding should be instructed not to take
ACCOLATE (see <a href="#williamsonbk1131388142070">PRECAUTIONS,
Nursing Mothers</a>). Alternative antiasthma medication should be
considered in such patients.</p>
<p>The bioavailability of ACCOLATE may be decreased when taken with
food. Patients should be instructed to take ACCOLATE at least 1
hour before or 2 hours after meals.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"powellk11242667207548" id="powellk11242667207548"></a> <a name=
"section-6.2" id="section-6.2"></a>
<h2>Eosinophilic Conditions:</h2>
<p class="First">In rare cases, patients with asthma on ACCOLATE
may present with systemic eosinophilia, eosinophilic pneumonia, or
clinical features of vasculitis consistent with Churg-Strauss
syndrome, a condition which is often treated with systemic steroid
therapy. Physicians should be alert to eosinophilia, vasculitic
rash, worsening pulmonary symptoms, cardiac complications, and/or
neuropathy presenting in their patients. These events have usually,
but not always, been associated with reductions and/or withdrawal
of steroid therapy. The possibility that ACCOLATE may be associated
with emergence of Churg-Strauss syndrome can neither be excluded
nor established (see <a href="#williamsonbk1131387977133">ADVERSE
REACTIONS</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"powellk11242666522624" id="powellk11242666522624"></a> <a name=
"section-6.3" id="section-6.3"></a>
<h2>Neuropsychiatric Events:</h2>
<p class="First">Neuropsychiatric events have been reported in
adult, adolescent and pediatric patients taking ACCOLATE.
Post-marketing reports with ACCOLATE include insomnia and
depression. The clinical details of some post-marketing reports
involving ACCOLATE appear consistent with a drug-induced effect.
Patients and prescribers should be alert for neuropsychiatric
events. Patients should be instructed to notify their prescriber if
these changes occur. Prescribers should carefully evaluate the
risks and benefits of continuing treatment with ACCOLATE if such
events occur (see <a href="#williamsonbk1131387977133">ADVERSE
REACTIONS</a>).</p>
</div>
<div class="Section" data-sectioncode="34073-7"><a name=
"williamsonbk1131387802291" id="williamsonbk1131387802291"></a>
<a name="section-6.4" id="section-6.4"></a>
<h2>Drug Interactions:</h2>
<p class="First">In a drug interaction study in 16 healthy male
volunteers, coadministration of multiple doses of zafirlukast (160
mg/day) to steady-state with a single 25 mg dose of warfarin
resulted in a significant increase in the mean AUC (+ 63%) and
half-life (+36%) of S-warfarin. The mean prothrombin time (PT)
increased by approximately 35%. This interaction is probably due to
an inhibition by zafirlukast of the cytochrome P450 2C9 isoenzyme
system. Patients on oral warfarin anticoagulant therapy and
ACCOLATE should have their prothrombin times monitored closely and
anticoagulant dose adjusted accordingly (see <a href=
"#williamsonbk1131388212897">WARNINGS, Concomitant Warfarin
Administration</a>). No formal drug-drug interaction studies with
ACCOLATE and other drugs known to be metabolized by the cytochrome
P450 2C9 isoenzyme (eg, tolbutamide, phenytoin, carbamazepine) have
been conducted; however, care should be exercised when ACCOLATE is
coadministered with these drugs.</p>
<p>In a drug interaction study in 11 asthmatic patients,
coadministration of a single dose of zafirlukast (40 mg) with
erythromycin (500 mg three times daily for 5 days) to steady-state
resulted in decreased mean plasma levels of zafirlukast by
approximately 40% due to a decrease in zafirlukast
bioavailability.</p>
<p>Coadministration of zafirlukast (20 mg/day) or placebo at
steady-state with a single dose of sustained release theophylline
preparation (16 mg/kg) in 16 healthy boys and girls (6 through 11
years of age) resulted in no significant differences in the
pharmacokinetic parameters of theophylline.</p>
<p>Coadministration of zafirlukast (80 mg/day) at steady-state with
a single dose of a liquid theophylline preparation (6 mg/kg) in 13
asthmatic patients, 18 to 44 years of age, resulted in decreased
mean plasma levels of zafirlukast by approximately 30%, but no
effect on plasma theophylline levels was observed.</p>
<p>Rare cases of patients experiencing increased theophylline
levels with or without clinical signs or symptoms of theophylline
toxicity after the addition of ACCOLATE to an existing theophylline
regimen have been reported. The mechanism of the interaction
between ACCOLATE and theophylline in these patients is unknown (see
<a href="#williamsonbk1131387977133">ADVERSE REACTIONS</a>).</p>
<p>Coadministration of zafirlukast (40 mg/day) with aspirin (650 mg
four times daily) resulted in mean increased plasma levels of
zafirlukast by approximately 45%.</p>
<p>In a single-blind, parallel-group, 3-week study in 39 healthy
female subjects taking oral contraceptives, 40 mg twice daily of
zafirlukast had no significant effect on ethinyl estradiol plasma
concentrations or contraceptive efficacy.</p>
<p>Coadministration of zafirlukast with fluconazole, a moderate
CYP2C9 inhibitor, resulted in increased</p>
<p>plasma levels of zafirlukast, by approximately 58% (90% CI:28,
95). The clinical significance of this</p>
<p>interaction is unknown. Zafirlukast exposure is likely to be
increased by other moderate and strong</p>
<p>CYP2C9 inhibitors. Coadministration of zafirlukast with
itraconazole, a strong CYP3A4 inhibitor, caused</p>
<p>no change in plasma levels of zafirlukast.</p>
<p>No other formal drug-drug interaction studies between ACCOLATE
and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4)
isoenzyme (eg, dihydropyridine calcium-channel blockers,
cyclosporin, cisapride) have been conducted. As ACCOLATE is known
to be an inhibitor of CYP3A4 <span class="Italics">in vitro</span>,
it is reasonable to employ appropriate clinical monitoring when
these drugs are coadministered with ACCOLATE.</p>
</div>
<div class="Section" data-sectioncode="34083-6"><a name=
"ID_99b18466-305c-43a7-419b-c9f076ec6616" id=
"ID_99b18466-305c-43a7-419b-c9f076ec6616"></a> <a name=
"section-6.5" id="section-6.5"></a>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">In two-year carcinogenicity studies, zafirlukast
was administered at dietary doses of 10, 100, and 300 mg/kg to mice
and 40, 400, and 2000 mg/kg to rats. Male mice at an oral dose of
300 mg/kg/day (approximately 30 times the maximum recommended daily
oral dose in adults and in children on a mg/m<span class=
"Sup">2</span> basis) showed an increased incidence of
hepatocellular adenomas; female mice at this dose showed a greater
incidence of whole body histocytic sarcomas. Male and female rats
at an oral dose of 2000 mg/kg/day (resulting in approximately 160
times the exposure to drug plus metabolites from the maximum
recommended daily oral dose in adults and in children based on a
comparison of the plasma area-under the curve [AUC] values) of
zafirlukast showed an increased incidence of urinary bladder
transitional cell papillomas. Zafirlukast was not tumorigenic at
oral doses up to 100 mg/kg (approximately 10 times the maximum
recommended daily oral dose in adults and in children on a
mg/m<span class="Sup">2</span> basis) in mice and at oral doses up
to 400 mg/kg (resulting in approximately 140 times the exposure to
drug plus metabolites from the maximum recommended daily oral dose
in adults and in children based on a comparison of the plasma AUC
values) in rats. The clinical significance of these findings for
the long-term use of ACCOLATE is unknown.</p>
<p>Zafirlukast showed no evidence of mutagenic potential in the
reverse microbial assay, in 2 forward point mutation (CHO-HGPRT and
mouse lymphoma) assays or in two assays for chromosomal aberrations
(the <span class="Italics">in vitro</span> human peripheral blood
lymphocyte clastogenic assay and the <span class="Italics">in
vivo</span> rat bone marrow micronucleus assay).</p>
<p>No evidence of impairment of fertility and reproduction was seen
in male and female rats treated with zafirlukast at oral doses up
to 2000 mg/kg (approximately 410 times the maximum recommended
daily oral dose in adults on a mg/m<span class="Sup">2</span>
basis).</p>
<div class="Section" data-sectioncode="42228-7"><a name=
"ID_02f13e7d-2a60-4296-8c82-99380dac0598" id=
"ID_02f13e7d-2a60-4296-8c82-99380dac0598"></a> <a name=
"section-6.5.1" id="section-6.5.1"></a>
<h3><span class="Italics">Pregnancy Category B:</span></h3>
<p class="First">No teratogenicity was observed at oral doses up to
1600 mg/kg/day in mice (approximately 160 times the maximum
recommended daily oral dose in adults on a mg/m<span class=
"Sup">2</span> basis), up to 2000 mg/kg/day in rats (approximately
410 times the maximum recommended daily oral dose in adults on a
mg/m<span class="Sup">2</span> basis) and up to 2000 mg/kg/day in
cynomolgus monkeys (which resulted in approximately 20 times the
exposure to drug plus metabolites compared to that from the maximum
recommended daily oral dose in adults based on comparison of the
AUC values). At an oral dose of 2000 mg/kg/day in rats, maternal
toxicity and deaths were seen with increased incidence of early
fetal resorption. Spontaneous abortions occurred in cynomolgus
monkeys at the maternally toxic oral dose of 2000 mg/kg/day. There
are no adequate and well-controlled trials in pregnant women.
Because animal reproductive studies are not always predictive of
human response, ACCOLATE should be used during pregnancy only if
clearly needed.</p>
</div>
<div class="Section" data-sectioncode="34080-2"><a name=
"williamsonbk1131388142070" id="williamsonbk1131388142070"></a>
<a name="section-6.5.2" id="section-6.5.2"></a>
<h3><span class="Italics">Nursing Mothers:</span></h3>
<p class="First">Zafirlukast is excreted in breast milk. Following
repeated 40 mg twice-a-day dosing in healthy women, average
steady-state concentrations of zafirlukast in breast milk were 50
ng/mL compared to 255 ng/mL in plasma. Because of the potential for
tumorigenicity shown for zafirlukast in mouse and rat studies and
the enhanced sensitivity of neonatal rats and dogs to the adverse
effects of zafirlukast, ACCOLATE should not be administered to
mothers who are breast-feeding.</p>
</div>
<div class="Section" data-sectioncode="34081-0"><a name=
"ID_4c0cedb3-5104-49c3-d4ad-228210d35e39" id=
"ID_4c0cedb3-5104-49c3-d4ad-228210d35e39"></a> <a name=
"section-6.5.3" id="section-6.5.3"></a>
<h3>Pediatric Use:</h3>
<p class="First">The safety of ACCOLATE at doses of 10 mg twice
daily has been demonstrated in 205 pediatric patients 5 through 11
years of age in placebo-controlled trials lasting up to six weeks
and with 179 patients in this age range participating in 52 weeks
of treatment in an open-label extension.</p>
<p>The effectiveness of ACCOLATE for the prophylaxis and chronic
treatment of asthma in pediatric patients 5 through 11 years of age
is based on an extrapolation of the demonstrated efficacy of
ACCOLATE in adults with asthma and the likelihood that the disease
course, and pathophysiology and the drug’s effect are substantially
similar between the two populations. The recommended dose for the
patients 5 through 11 years of age is based upon a cross-study
comparison of the pharmacokinetics of zafirlukast in adults and
pediatric subjects, and on the safety profile of zafirlukast in
both adult and pediatric patients at doses equal to or higher than
the recommended dose.</p>
<p>The safety and effectiveness of zafirlukast for pediatric
patients less than 5 years of age has not been established. The
effect of ACCOLATE on growth in children has not been
determined.</p>
</div>
<div class="Section" data-sectioncode="34082-8"><a name=
"ID_ee8cbc6b-9a9b-4b6b-ecaa-da40ce6361c0" id=
"ID_ee8cbc6b-9a9b-4b6b-ecaa-da40ce6361c0"></a> <a name=
"section-6.5.4" id="section-6.5.4"></a>
<h3><span class="Italics">Geriatric Use:</span></h3>
<p class="First">Based on cross-study comparison, the clearance of
zafirlukast is reduced in patients 65 years of age and older such
that C<span class="Sub">max</span> and AUC are approximately 2- to
3-fold greater than those of younger patients (see <a href=
"#williamsonbk1131387848681">DOSAGE AND ADMINISTRATION</a> and
<a href="#williamsonbk1131388273647">CLINICAL
PHARMACOLOGY</a>).</p>
<p>A total of 8094 patients were exposed to zafirlukast in North
American and European short-term placebo-controlled clinical
trials. Of these, 243 patients were elderly (age 65 years and
older). No overall difference in adverse events was seen in the
elderly patients, except for an increase in the frequency of
infections among zafirlukast-treated elderly patients compared to
placebo-treated elderly patients (7.0% vs. 2.9%). The infections
were not severe, occurred mostly in the lower respiratory tract,
and did not necessitate withdrawal of therapy.</p>
<p>An open-label, uncontrolled, 4-week trial of 3759 asthma
patients compared the safety and efficacy of ACCOLATE 20 mg given
twice daily in three patient age groups, adolescents (12-17 years),
adults (18-65 years), and elderly (greater than 65 years). A higher
percentage of elderly patients (n=384) reported adverse events when
compared to adults and adolescents. These elderly patients showed
less improvement in efficacy measures. In the elderly patients,
adverse events occurring in greater than 1% of the population
included headache (4.7%), diarrhea and nausea (1.8%), and
pharyngitis (1.3%). The elderly reported the lowest percentage of
infections of all three age groups in this study.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="williamsonbk1131387977133" id=
"williamsonbk1131387977133"></a> <a name="section-7" id=
"section-7"></a>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_d424c4e0-8743-40e7-beac-f61124f7becf" id=
"ID_d424c4e0-8743-40e7-beac-f61124f7becf"></a> <a name=
"section-7.1" id="section-7.1"></a>
<h2>Adults and Children 12 years of age and older</h2>
<p class="First">The safety database for ACCOLATE consists of more
than 4000 healthy volunteers and patients who received ACCOLATE, of
which 1723 were asthmatics enrolled in trials of 13 weeks duration
or longer. A total of 671 patients received ACCOLATE for 1 year or
longer. The majority of the patients were 18 years of age or older;
however, 222 patients between the age of 12 and 18 years received
ACCOLATE.</p>
<p>A comparison of adverse events reported by ≥1% of
zafirlukast-treated patients, and at rates numerically greater than
in placebo-treated patients, is shown for all trials in the table
below.</p>
<div class="scrollingtable">
<table>
<colgroup>
<col width="19%">
<col width="15%">
<col width="13%"></colgroup>
<tbody class="Headless">
<tr class="First Toprule">
<td valign="top"></td>
<td align="center" valign="top">
<p class="First">ACCOLATE</p>
</td>
<td align="center" valign="top">
<p class="First">PLACEBO</p>
</td>
</tr>
<tr>
<td class="Botrule" valign="top">
<p class="First">Adverse Event</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">N=4058</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">N=2032</p>
</td>
</tr>
<tr>
<td class="Toprule" valign="top">
<p class="First">Headache</p>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First">12.9%</p>
</td>
<td class="Toprule" align="center" valign="top">
<p class="First">11.7%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Infection</p>
</td>
<td align="center" valign="top">
<p class="First">3.5%</p>
</td>
<td align="center" valign="top">
<p class="First">3.4%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Nausea</p>
</td>
<td align="center" valign="top">
<p class="First">3.1%</p>
</td>
<td align="center" valign="top">
<p class="First">2.0%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Diarrhea</p>
</td>
<td align="center" valign="top">
<p class="First">2.8%</p>
</td>
<td align="center" valign="top">
<p class="First">2.1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Pain (generalized)</p>
</td>
<td align="center" valign="top">
<p class="First">1.9%</p>
</td>
<td align="center" valign="top">
<p class="First">1.7%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Asthenia</p>
</td>
<td align="center" valign="top">
<p class="First">1.8%</p>
</td>
<td align="center" valign="top">
<p class="First">1.6%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Abdominal Pain</p>
</td>
<td align="center" valign="top">
<p class="First">1.8%</p>
</td>
<td align="center" valign="top">
<p class="First">1.1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Accidental Injury</p>
</td>
<td align="center" valign="top">
<p class="First">1.6%</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Dizziness</p>
</td>
<td align="center" valign="top">
<p class="First">1.6%</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Myalgia</p>
</td>
<td align="center" valign="top">
<p class="First">1.6%</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Fever</p>
</td>
<td align="center" valign="top">
<p class="First">1.6%</p>
</td>
<td align="center" valign="top">
<p class="First">1.1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Back Pain</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
<td align="center" valign="top">
<p class="First">1.2%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">Vomiting</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
<td align="center" valign="top">
<p class="First">1.1%</p>
</td>
</tr>
<tr>
<td valign="top">
<p class="First">SGPT Elevation</p>
</td>
<td align="center" valign="top">
<p class="First">1.5%</p>
</td>
<td align="center" valign="top">
<p class="First">1.1%</p>
</td>
</tr>
<tr class="Botrule Last">
<td class="Botrule" valign="top">
<p class="First">Dyspepsia</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">1.3%</p>
</td>
<td class="Botrule" align="center" valign="top">
<p class="First">1.2%</p>
</td>
</tr>
</tbody>
</table>
</div>
<p>The frequency of less common adverse events was comparable
between ACCOLATE and placebo.</p>
<p>Rarely, elevations of one or more liver enzymes have occurred in
patients receiving ACCOLATE in controlled clinical trials. In
clinical trials, most of these have been observed at doses four
times higher than the recommended dose. The following hepatic
events (which have occurred predominantly in females) have been
reported from postmarketing adverse event surveillance of patients
who have received the recommended dose of ACCOLATE (40 mg/day):
cases of symptomatic hepatitis (with or without hyperbilirubinemia)
without other attributable cause; and rarely, hyperbilirubinemia
without other elevated liver function tests. In most, but not all
postmarketing reports, the patient’s symptoms abated and the liver
enzymes returned to normal or near normal after stopping ACCOLATE.
In rare cases, patients have presented with fulminant hepatitis or
progressed to hepatic failure, liver transplantation and death (see
<a href="#williamsonbk1131388093117">WARNINGS, Hepatotoxicity</a>
and <a href="#williamsonbk1131387955212">PRECAUTIONS, Information
for Patients</a>).</p>
<p>In clinical trials, an increased proportion of zafirlukast
patients over the age of 55 years reported infections as compared
to placebo-treated patients. A similar finding was not observed in
other age groups studied. These infections were mostly mild or
moderate in intensity and predominantly affected the respiratory
tract. Infections occurred equally in both sexes, were
dose-proportional to total milligrams of zafirlukast exposure, and
were associated with coadministration of inhaled corticosteroids.
The clinical significance of this finding is unknown.</p>
<p>In rare cases, patients with asthma on ACCOLATE may present with
systemic eosinophilia, eosinophilic pneumonia, or clinical features
of vasculitis consistent with Churg-Strauss syndrome, a condition
which is often treated with systemic steroid therapy. Physicians
should be alert to eosinophilia, vasculitic rash, worsening
pulmonary symptoms, cardiac complications, and/or neuropathy
presenting in their patients. These events have usually, but not
always, been associated with reductions and/or withdrawal of
steroid therapy. The possibility that ACCOLATE may be associated
with emergence of Churg-Strauss syndrome can neither be excluded
nor established (see <a href="#powellk11242667207548">PRECAUTIONS,
Eosinophilic Conditions</a>).</p>
<p>Neuropsychiatric adverse events, including insomnia and
depression, have been reported in association with ACCOLATE therapy
(see <a href="#powellk11242666522624">PRECAUTIONS, Neuropsychiatric
Events</a>). Hypersensitivity reactions, including urticaria,
angioedema and rashes, with or without blistering, have also been
reported in association with ACCOLATE therapy. Additionally, there
have been reports of patients experiencing agranulocytosis,
bleeding, bruising, or edema, arthralgia, myalgia, malaise, and
pruritus in association with ACCOLATE therapy.</p>
<p>Rare cases of patients experiencing increased theophylline
levels with or without clinical signs or symptoms of theophylline
toxicity after the addition of ACCOLATE to an existing theophylline
regimen have been reported. The mechanism of the interaction
between ACCOLATE and theophylline in these patients is unknown and
not predicted by available <span class="Italics">in vitro</span>
metabolism data and the results of two clinical drug interaction
studies (see <a href="#williamsonbk1131388273647">CLINICAL
PHARMACOLOGY</a> and <a href=
"#williamsonbk1131387802291">PRECAUTIONS, Drug
Interactions</a>).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_d30f8371-8629-4fee-9983-ee6122083f4b" id=
"ID_d30f8371-8629-4fee-9983-ee6122083f4b"></a> <a name=
"section-7.2" id="section-7.2"></a>
<h2>Pediatric Patients 5 through 11 years of age</h2>
<p class="First">ACCOLATE has been evaluated for safety in 788
pediatric patients 5 through 11 years of age. Cumulatively, 313
pediatric patients were treated with ACCOLATE 10 mg twice daily or
higher for at least 6 months, and 113 of them were treated for one
year or longer in clinical trials. The safety profile of ACCOLATE
10 mg twice daily-versus placebo in the 4- and 6-week double-blind
trials was generally similar to that observed in the adult clinical
trials with ACCOLATE 20 mg twice daily.</p>
<p>In pediatric patients receiving ACCOLATE in multi-dose clinical
trials, the following events occurred with a frequency of ≥ 2% and
more frequently than in pediatric patients who received placebo,
regardless of causality assessment: headache (4.5 vs. 4.2%) and
abdominal pain (2.8 vs. 2.3%).</p>
<p>The post-marketing experience in this age group is similar to
that seen in adults, including hepatic dysfunction, which may lead
to liver failure.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="ID_ed2ed066-61fc-4267-3a8a-b96bd17b7a3e" id=
"ID_ed2ed066-61fc-4267-3a8a-b96bd17b7a3e"></a> <a name="section-8"
id="section-8"></a>
<p class="First">No deaths occurred at oral zafirlukast doses of
2000 mg/kg in mice (approximately 210 times the maximum recommended
daily oral dose in adults and children on a mg/m<span class=
"Sup">2</span> basis), 2000 mg/kg in rats (approximately 420 times
the maximum recommended daily oral dose in adults and children on a
mg/m<span class="Sup">2</span> basis), and 500 mg/kg in dogs
(approximately 350 times the maximum recommended daily oral dose in
adults and children on a mg/m<span class="Sup">2</span> basis).</p>
<p>Overdosage with ACCOLATE has been reported in four patients
surviving reported doses as high as 200 mg. The predominant
symptoms reported following ACCOLATE overdose were rash and upset
stomach. There were no acute toxic effects in humans that could be
consistently ascribed to the administration of ACCOLATE. It is
reasonable to employ the usual supportive measures in the event of
an overdose; eg, remove unabsorbed material from the
gastrointestinal tract, employ clinical monitoring, and institute
supportive therapy, if required.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="williamsonbk1131387848681" id=
"williamsonbk1131387848681"></a> <a name="section-9" id=
"section-9"></a>
<p class="First">Because food can reduce the bioavailability of
zafirlukast, ACCOLATE should be taken at least 1 hour before or 2
hours after meals.</p>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_79233351-b4ee-403b-a36f-d76c65f7de70" id=
"ID_79233351-b4ee-403b-a36f-d76c65f7de70"></a> <a name=
"section-9.1" id="section-9.1"></a>
<h2>Adults and Children 12 years of age and older</h2>
<p class="First">The recommended dose of ACCOLATE in adults and
children 12 years and older is 20 mg twice daily.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_437d381d-d997-4353-afc3-116201110f57" id=
"ID_437d381d-d997-4353-afc3-116201110f57"></a> <a name=
"section-9.2" id="section-9.2"></a>
<h2>Pediatric Patients 5 through 11 years of age</h2>
<p class="First">The recommended dose of ACCOLATE in children 5
through 11 years of age is 10 mg twice daily.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_c0570525-a602-4e8c-870a-ee16982943ef" id=
"ID_c0570525-a602-4e8c-870a-ee16982943ef"></a> <a name=
"section-9.3" id="section-9.3"></a>
<h2>Elderly Patients</h2>
<p class="First">Based on cross-study comparisons, the clearance of
zafirlukast is reduced in elderly patients (65 years of age and
older), such that C<span class="Sub">max</span> and AUC are
approximately twice those of younger adults. In clinical trials, a
dose of 20 mg twice daily was not associated with an increase in
the overall incidence of adverse events or withdrawals because of
adverse events in elderly patients.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_0e0170d3-b1c2-4e5c-9d61-ce1a68baf330" id=
"ID_0e0170d3-b1c2-4e5c-9d61-ce1a68baf330"></a> <a name=
"section-9.4" id="section-9.4"></a>
<h2>Patients with Hepatic Impairment</h2>
<p class="First">ACCOLATE is contraindicated in patients with
hepatic impairment including hepatic cirrhosis (see
Contraindications). The clearance of zafirlukast is reduced in
patients with stable alcoholic cirrhosis such that the
C<span class="Sub">max</span> and AUC are approximately 50 - 60%
greater than those of normal adults. ACCOLATE has not been
evaluated in patients with hepatitis or in long-term studies of
patients with cirrhosis.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name=
"ID_0907566f-0c71-4c79-923a-c0756d4a26ee" id=
"ID_0907566f-0c71-4c79-923a-c0756d4a26ee"></a> <a name=
"section-9.5" id="section-9.5"></a>
<h2>Patients with Renal Impairment</h2>
<p class="First">Dosage adjustment is not required for patients
with renal impairment.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HOW SUPPLIED</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="ID_72a56be5-e068-48a4-5bb7-00ba4b81800a" id=
"ID_72a56be5-e068-48a4-5bb7-00ba4b81800a"></a> <a name="section-10"
id="section-10"></a>
<p class="First"><span class="Bold">ACCOLATE 10 mg Tablets,</span>
(NDC 0310-0401) white, unflavored, round, biconvex, film-coated,
mini-tablets identified with “ACCOLATE 10” debossed on one side are
supplied in opaque HDPE bottles of 60 tablets.</p>
<p><span class="Bold">ACCOLATE 20 mg Tablets,</span> (NDC
0310-0402) white, round, biconvex, coated tablets identified with
“ACCOLATE 20” debossed on one side are supplied in opaque HDPE
bottles of 60 tablets.</p>
<p>Store at controlled room temperature, 20-25°C (68-77°F) [see
USP]. Protect from light and moisture. Dispense in the original
air-tight container.</p>
<p>ACCOLATE is a trademark of the AstraZeneca group of
companies.</p>
<p><span class="Sup">©</span>AstraZeneca 2013</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>Rev. 11/2013</p>
<p>AstraZeneca</p>
<p><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">ACCOLATE<span class="Sup">®</span>
(ak-o-late)</span></p>
<p><span class="Bold">(zafirlukast) Tablets</span></p>
<p>Read the Patient Information leaflet before you start taking
ACCOLATE and each time you get a refill. There may be new
information. This information does not take the place of talking to
your healthcare provider about your medical condition or your
treatment.</p>
<p><span class="Bold">What is ACCOLATE?</span></p>
<p>ACCOLATE is a prescription medicine used to help prevent asthma
attacks and for the long-term treatment of asthma symptoms in
adults and children 5 years and older.</p>
<p>It is not known if ACCOLATE is safe and effective when used in
children under 5 years old. The effect of ACCOLATE on growth in
children has not been determined.</p>
<p>Do not take ACCOLATE if you need relief right away for a sudden
asthma attack. If you get an asthma attack, you should follow the
instructions your healthcare provider gave you for treating asthma
attacks.</p>
<p><span class="Bold">Who should not take ACCOLATE?</span></p>
<p>Do not take ACCOLATE if you;</p>
<dl>
<dt>•</dt>
<dd>are allergic to zafirlukast or any of the ingredients in
ACCOLATE. See the end of this leaflet for a complete list of
ingredients in ACCOLATE.</dd>
<dt>•</dt>
<dd>have problems with your liver.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider
before taking ACCOLATE?</span></p>
<p><span class="Bold">Before you take ACCOLATE, tell your
healthcare provider if you:</span></p>
<dl>
<dt>•</dt>
<dd>have liver problems</dd>
<dt>•</dt>
<dd>have any other medical conditions</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if
ACCOLATE will harm your unborn baby. Talk to your healthcare
provider if you are pregnant or plan to become pregnant.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. ACCOLATE can pass into
your milk; it is not known whether ACCOLATE may harm your baby.
Women who are breastfeeding should not take ACCOLATE.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the
medicines you take,</span> including prescription and
non-prescription medicines, vitamins, and herbal supplements.</p>
<p>ACCOLATE may affect the way other medicines work, and other
medicines may affect how ACCOLATE works.</p>
<p><span class="Bold">Especially tell your healthcare provider if
you take:</span></p>
<dl>
<dt>•</dt>
<dd>warfarin sodium (Coumadin, Jantoven)</dd>
<dt>•</dt>
<dd>erythromycin (ERYC, ERY-TAB, PCE)</dd>
<dt>•</dt>
<dd>theophylline (Elixophyllin, Theo-24, Theochron, Theolair,
Uniphyl)</dd>
<dt>•</dt>
<dd>fluconazole (Diflucan)</dd>
</dl>
<p>Know the medicines you take. Keep a list of them to show your
healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ACCOLATE?</span></p>
<dl>
<dt>•</dt>
<dd>Take ACCOLATE exactly as your healthcare provider tells you to
take it.</dd>
<dt>•</dt>
<dd>Take ACCOLATE regularly, even if you do not have asthma
symptoms. Do not change your dose or stop taking ACCOLATE without
talking to your healthcare provider.</dd>
<dt>•</dt>
<dd>Do not stop taking or change the dose of your other asthma
medicines unless your healthcare provider tells you to.</dd>
<dt>•</dt>
<dd>Take your prescribed dose of ACCOLATE by mouth at least 1 hour
before or 2 hours after meals.</dd>
<dt>•</dt>
<dd>ACCOLATE does not treat the symptoms of a sudden asthma attack.
Always have a short-acting beta <span class="Sub">2</span>-agonist
medicine (rescue inhaler) with you to treat sudden symptoms. If you
do not have a rescue inhaler medicine, talk to your healthcare
provider to have one prescribed for you.</dd>
<dt>•</dt>
<dd>If you take too much ACCOLATE, call your healthcare provider or
go to the nearest hospital emergency room right away.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of
ACCOLATE?</span></p>
<p><span class="Bold">ACCOLATE may cause serious side effects,
including:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Severe liver problems.</span> In some cases,
these liver problems can lead to liver failure, the need for a
liver transplant or death. Tell your healthcare provider right away
if you have:</dd>
<dt>•</dt>
<dd>pain or tenderness in the right upper side of your stomach area
(abdomen)</dd>
<dt>•</dt>
<dd>nausea</dd>
<dt>•</dt>
<dd>tiredness</dd>
<dt>•</dt>
<dd>itchiness</dd>
<dt>•</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
<dt>•</dt>
<dd>flu-like symptoms</dd>
<dt>•</dt>
<dd>loss of appetite</dd>
<dt>•</dt>
<dd>dark (tea colored) urine</dd>
<dt>•</dt>
<dd><span class="Bold">Inflammation of your blood vessels.</span>
Rarely, this can happen in people with asthma who take ACCOLATE.
This usually, but not always, happens in people who also take a
steroid medicine by mouth that is being stopped or the dose is
being lowered. Tell your healthcare provider right away if you
have:
<dl>
<dt>o</dt>
<dd>a feeling of pins and needles or numbness of your arms or
legs</dd>
<dt>o</dt>
<dd>flu like symptoms</dd>
<dt>o</dt>
<dd>rash</dd>
<dt>o</dt>
<dd>pain and swelling of your sinuses</dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold">Changes in behaviour or mood.</span> Tell
your healthcare provider if you have changes in your behaviour,
problems sleeping or feel very sad.</dd>
<dt>•</dt>
<dd><span class="Bold">Hypersensitivity reactions.</span> Tell your
healthcare provider if you have severe itching, breathing problems,
skin rash, skin blisters, or skin redness, or swelling.</dd>
</dl>
<p>The most common side effects of ACCOLATE in people 12 years and
older include:</p>
<dl>
<dt>•</dt>
<dd>headache</dd>
<dt>•</dt>
<dd>infection</dd>
<dt>•</dt>
<dd>nausea</dd>
<dt>•</dt>
<dd>diarrhea</dd>
<dt>•</dt>
<dd>pain (generalized)</dd>
</dl>
<p>The most common side effects of ACCOLATE in children 5 to 11
years include:</p>
<dl>
<dt>•</dt>
<dd>headache</dd>
<dt>•</dt>
<dd>stomach pain</dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that
bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of ACCOLATE. For
more information, ask your healthcare provider or pharmacist.</p>
<p>Call your healthcare provider for medical advice about side
effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>You may also report side effects to AstraZeneca at
1-800-236-9933.</p>
<p><span class="Bold">How should I store ACCOLATE?</span></p>
<dl>
<dt>•</dt>
<dd>Store ACCOLATE at 68°F to 77°F (20°C -25°C).</dd>
<dt>•</dt>
<dd>Keep ACCOLATE tablets dry.</dd>
<dt>•</dt>
<dd>Keep ACCOLATE in a tight closed container and keep ACCOLATE out
of the light.</dd>
<dt>•</dt>
<dd>Keep ACCOLATE and all medicines out of the reach of
children.</dd>
</dl>
<p><span class="Bold">General information about the safe and
effective use of ACCOLATE.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
listed in a Patient Information leaflet. Do not use ACCOLATE for a
condition for which it was not prescribed. Do not give ACCOLATE to
other people, even if they have the same symptoms that you have. It
may harm them.</p>
<p>This Patient Information leaflet summarizes the most important
information about ACCOLATE. If you would like more information,
talk with your healthcare provider. You can ask your pharmacist or
healthcare provider for information about ACCOLATE that is written
for healthcare professionals.</p>
<p>For more information, go to www.accolate.com or call AstraZeneca
Information Center at 1-800-236-9933, Monday through Friday, 8 a.m.
– 6 p.m. Eastern Standard Time, excluding holidays.</p>
<p><span class="Bold">What are the ingredients in
ACCOLATE?</span></p>
<p><span class="Bold">Active ingredient:</span> zafirlukast</p>
<p><span class="Bold">Inactive ingredients:</span> croscarmellose
sodium, lactose, magnesium stearate, microcrystalline cellulose,
povidone, hypromellose, and titanium dioxide.</p>
<p><span class="Bold">What do ACCOLATE tablets look
like?</span></p>
<dl>
<dt>•</dt>
<dd>the 10 mg tablet is white and round with “ACCOLATE 10” marked
on one side.</dd>
<dt>•</dt>
<dd>the 20 mg tablet is white and round with “ACCOLATE 20” marked
on one side.</dd>
</dl>
<p>ACCOLATE is a trademark of the AstraZeneca group of
companies.</p>
<p>©AstraZeneca 2013</p>
<p>Distributed by:</p>
<p>AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>Rev. 11/2013</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 10 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_5d24778c-e857-42bf-9b59-74d90fc2cf2d" id=
"ID_5d24778c-e857-42bf-9b59-74d90fc2cf2d"></a> <a name="section-11"
id="section-11"></a>
<p class="First">NDC 0310-0401-60</p>
<p>60 tablets</p>
<p>ACCOLATE®</p>
<p>ZAFIRLUKAST</p>
<p>10 mg tablets</p>
<p>Rx only</p>
<p>DISPENSE IN THE ORIGINAL</p>
<p>AIRTIGHT CONTAINER.</p>
<p>Mfd. for: AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By: IPR Pharmaceuticals, Inc.</p>
<p>Canóvanas, PR 00729</p>
<p>Product of UK</p>
<p>AstraZeneca</p>
<div class="Figure"><a name="id208298887" id="id208298887"></a>
<img src=
"image.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-03.jpg"
alt="ACCOLATE 10 mg tablets Bottle Label 60 tablets"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 20 mg</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="ID_aa379360-2b98-4fdf-8fd5-62fedb23df3f" id=
"ID_aa379360-2b98-4fdf-8fd5-62fedb23df3f"></a> <a name="section-12"
id="section-12"></a>
<p class="First">NDC 0310-0402-60</p>
<p>60 tablets</p>
<p>ACCOLATE®</p>
<p>ZAFIRLUKAST</p>
<p>20 mg tablets</p>
<p>Rx only</p>
<p>DISPENSE IN THE ORIGINAL</p>
<p>AIRTIGHT CONTAINER.</p>
<p>Mfd. for: AstraZeneca Pharmaceuticals LP</p>
<p>Wilmington, DE 19850</p>
<p>By: IPR Pharmaceuticals, Inc.</p>
<p>Canóvanas, PR 00729</p>
<p>Product of UK</p>
<p>AstraZeneca</p>
<div class="Figure"><a name="id208299240" id="id208299240"></a>
<img src=
"image.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c&amp;name=2b0262a7-3717-4db6-8be7-f419812dda5f-04.jpg"
alt="ACCOLATE 20 mg tablets Bottle Label 60 tablets"></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>ACCOLATE</strong><br>
<span class="contentTableReg">zafirlukast tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0401</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ZAFIRLUKAST</strong> (UNII:
XZ629S5L50) (ZAFIRLUKAST - UNII:XZ629S5L50)</td>
<td class="formItem">ZAFIRLUKAST</td>
<td class="formItem">10 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex)</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACCOLATE10</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0310-0401-60</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020547</td>
<td class="formItem">10/01/1996</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>ACCOLATE</strong><br>
<span class="contentTableReg">zafirlukast tablet, film
coated</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0310-0402</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ZAFIRLUKAST</strong> (UNII:
XZ629S5L50) (ZAFIRLUKAST - UNII:XZ629S5L50)</td>
<td class="formItem">ZAFIRLUKAST</td>
<td class="formItem">20 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong> (UNII:
M28OL1HH48)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong> (UNII:
EWQ57Q8I5X)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong> (UNII:
70097M6I30)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong> (UNII:
FZ989GH94E)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex)</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACCOLATE20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0310-0402-60</td>
<td class="formItem">60 in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020547</td>
<td class="formItem">10/01/1996</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> AstraZeneca Pharmaceuticals LP
(054743190)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Registrant -</span> AstraZeneca PLC
(230790719)</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Establishment</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Name</th>
<th class="formTitle" scope="col">Address</th>
<th class="formTitle" scope="col">ID/FEI</th>
<th class="formTitle" scope="col">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">IPR Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">156931248</td>
<td class="formItem">MANUFACTURE(0310-0401, 0310-0402)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22ZAFIRLUKAST%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=ZAFIRLUKAST"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=ZAFIRLUKAST"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00377&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">ACCOLATE- zafirlukast tablet, film
coated<br></h3>
<h4>Number of versions: 8</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Nov 20, 2013</td>
<td>11 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=124604">download</a></td>
</tr>
<tr>
<td>Sep 5, 2012</td>
<td>10</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=87316">download</a></td>
</tr>
<tr>
<td>Jan 20, 2012</td>
<td>9</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=71573">download</a></td>
</tr>
<tr>
<td>Mar 14, 2011</td>
<td>8</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=50413">download</a></td>
</tr>
<tr>
<td>Aug 6, 2010</td>
<td>7</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=26479">download</a></td>
</tr>
<tr>
<td>May 7, 2010</td>
<td>5</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=19018">download</a></td>
</tr>
<tr>
<td>Jan 11, 2008</td>
<td>2</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=6571">download</a></td>
</tr>
<tr>
<td>Dec 18, 2007</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=6421">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">ACCOLATE- zafirlukast tablet, film
coated<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=199655">199655</a></td>
<td>zafirlukast 20 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=199655">199655</a></td>
<td>zafirlukast 20 MG Oral Tablet</td>
<td>SCD</td>
</tr>
<tr class="psn-rxtty">
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=211776">211776</a></td>
<td>ACCOLATE 20 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=211776">211776</a></td>
<td>zafirlukast 20 MG Oral Tablet [Accolate]</td>
<td>SBD</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=211776">211776</a></td>
<td>Accolate 20 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=261313">261313</a></td>
<td>ACCOLATE 10 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=261313">261313</a></td>
<td>zafirlukast 10 MG Oral Tablet [Accolate]</td>
<td>SBD</td>
</tr>
<tr>
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=261313">261313</a></td>
<td>Accolate 10 MG Oral Tablet</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=313758">313758</a></td>
<td>zafirlukast 10 MG Oral Tablet</td>
<td>PSN</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=313758">313758</a></td>
<td>zafirlukast 10 MG Oral Tablet</td>
<td>SCD</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">ACCOLATE- zafirlukast tablet, film
coated<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=5550433b-8c9c-4378-058f-6bb724c4f18c</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0AACCOLATE%2D%20Zafirlukast%20Tablet%2C%20Film%20Coated%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D5550433b%2D8c9c%2D4378%2D058f%2D6bb724c4f18c%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "ACCOLATE- zafirlukast tablet, film coated <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
